Nonimmunologic targets of immunosuppressive agents in podocytes

Kidney Research and Clinical Practice

Volumn 34, Issue 2, 2015, Pages 69-75

  Yoo, Tae Hyun ^a,b   Fornoni, Alessia ^b  

^a Yonsei University College of Medicine   (South Korea)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Immunomodulation; Nephrotic syndrome; Podocyte; Proteinuria

Indexed keywords

ABATACEPT; B7 ANTIGEN; CALCINEURIN INHIBITOR; FINGOLIMOD; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RITUXIMAB;

ARTICLE; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84937524627     PISSN: 22119132     EISSN: 22119140     Source Type: Journal    
DOI: 10.1016/j.krcp.2015.03.003     Document Type: Review

References (67)

1. M Bonilla-Felix, C Parra, T Dajani, M Ferris, RD Swinford, RJ Portman, and R Verani Changing patterns in the histopathology of idiopathic NS in children Kidney Int 55 1999 1885 1890
2. M Haas, SM Meehan, TG Karrison, and BH Spargo Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997 Am J Kidney Dis 30 1997 621 631
3. H Pavenstädt, W Kriz, and M Kretzler Cell biology of the glomerular podocyte Physiol Rev 83 2003 253 307
4. K Tryggvason, and J Wartiovaara Molecular basis of glomerular permselectivity Curr Opin Nephrol Hypertens 10 2001 543 549
5. K Asanuma, K Kim, J Oh, L Giardino, S Chabanis, C Faul, J Reiser, and P Mundel Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner J Clin Invest 115 2005 1188 1198
6. AD Kistler, V Peev, AL Forst, S El Hindi, MM Altintas, and J Reiser Enzymatic disease of the podocyte Pediatr Nephrol 25 2010 1017 1023
7. A Meyrier Treatment of primary focal segmental glomerulosclerosis Nephrol Dial Transplant 14 1999 74 78
8. J Oh, and MJ Kemper Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome Expert Rev Clin Pharmacol 3 2010 527 537
9. PW Mathieson The podocyte as a target for therapies - new and old Nat Rev Nephrol 8 2012 52 56
10. RJ Shalhoub Pathogenesis of lipoid nephrosis: a disorder of T-cell function Lancet 2 1974 556 560
11. V Audard, F Larousserie, P Grimbert, M Abtahi, JJ Sotto, A Delmer, F Boue, D Nochy, N Brousse, R Delarue, P Remy, P Ronco, D Sahali, P Lang, and O Hermine Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature Kidney Int 69 2006 2251 2260
12. M Abdel-Hafez, M Shimada, PY Lee, RJ Johnson, and EH Garin Idiopathic nephrotic syndrome and atopy: is there a common link? Am J Kidney Dis 54 2009 945 953
13. C Frank, M Herrmann, S Fernandez, D Dirnecker, M Böswald, W Kolowos, H Ruder, and JP Haas Dominant T cells in idiopathic nephrotic syndrome of childhood Kidney Int 57 2000 510 517
14. TJ Neuhaus, M Wadhwa, R Callard, and TM Barratt Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome Clin Exp Immunol 100 1995 475 479
15. JG van den Berg, and JJ Weening Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome Clin Sci (Lond) 107 2004 125 136
16. C Ponticelli, and RJ. Glassock Glomerular diseases: membranous nephropathy - a modern view Clin J Am Soc Nephrol 9 2014 609 616
17. MP Winn, PJ Conlon, KL Lynn, MK Farrington, T Creazzo, AF Hawkins, N Daskalakis, SY Kwan, S Ebersviller, JL Burchette, MA Pericak-Vance, DN Howell, JM Vance, and PB Rosenberg A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis Science 308 2005 1801 1804
18. S Ambalavanan, JP Fauvel, RK Sibley, and BD Myers Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy J Am Soc Nephrol 7 1996 290 298
19. L Callís, A Vila, J Nieto, and G Fortuny Effect of cyclosporin A on proteinuria in patients with Alport's syndrome Pediatr Nephrol 6 1992 140 144
20. D Chen, B Jefferson, SJ Harvey, K Zheng, CJ Gartley, RM Jacobs, and PS Thorner Cyclosporine A slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): results from a canine model J Am Soc Nephrol 14 2003 690 698
21. M Malina, O Cinek, J Janda, and T Seeman Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation Pediatr Nephrol 24 2009 2051 2053
22. VJ Savin, ET McCarthy, and M Sharma Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis Kidney Res Clin Pract 31 2012 205 213
23. T Wada, JW Pippin, CB Marshall, SV Griffin, and SJ Shankland Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins J Am Soc Nephrol 16 2005 2615 2625
24. T Wada, JW Pippin, M Nangaku, and SJ Shankland Dexamethasone's prosurvival benefits in podocytes require extracellular signal-regulated kinase phosphorylation Nephron Exp Nephrol 109 2008 e8 e19
25. CY Xing, MA Saleem, RJ Coward, L Ni, IR Witherden, and PW Mathieson Direct effects of dexamethasone on human podocytes Kidney Int 70 2006 1038 1045
26. RF Ransom, NG Lam, MA Hallett, SJ Atkinson, and WE Smoyer Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization Kidney Int 68 2005 2473 2483
27. RS Mutch, and PR Hutson Levamisole in the adjuvant treatment of colon cancer Clin Pharm 10 1991 95 109
28. MS Sajid, Z Iqbal, G Muhammad, and MU Iqbal Immunomodulatory effect of various anti-parasitics: a review Parasitology 132 2006 301 313
29. C Szeto, KM Gillespie, and PW Mathieson Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance Immunology 100 2000 217 224
30. L Jiang, I Dasgupta, JA Hurcombe, HF Colyer, PW Mathieson, and GI Welsh Levamisole in steroid-sensitive nephrotic syndrome: usefulness in adult patients and laboratory insights into mechanisms of action via direct action on the kidney podocyte Clin Sci (Lond) 128 2015 883 893
31. DC Cattran, E Alexopoulos, P Heering, PF Hoyer, A Johnston, A Meyrier, C Ponticelli, T Saito, G Choukroun, P Nachman, M Praga, and N Yoshikawa Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations Kidney Int 72 2007 1429 1447
32. A Meyrier Treatment of idiopathic nephrosis by immunophillin modulation Nephrol Dial Transplant 18 2003 vi79 vi86
33. C Faul, M Donnelly, S Merscher-Gomez, YH Chang, S Franz, J Delfgaauw, JM Chang, HY Choi, KN Campbell, K Kim, J Reiser, and P Mundel The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A Nat Med 14 2008 931 938
34. J Reiser, KR Polu, CC Möller, P Kenlan, MM Altintas, C Wei, C Faul, S Herbert, I Villegas, C Avila-Casado, M McGee, H Sugimoto, D Brown, R Kalluri, P Mundel, PL Smith, DE Clapham, and MR Pollak TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function Nat Genet 37 2005 739 744
35. CC Möller, C Wei, MM Altintas, J Li, A Greka, T Ohse, JW Pippin, MP Rastaldi, S Wawersik, S Schiavi, A Henger, M Kretzler, SJ Shankland, and J Reiser Induction of TRPC6 channel in acquired forms of proteinuric kidney disease J Am Soc Nephrol 18 2007 29 36
36. T Nijenhuis, AJ Sloan, JG Hoenderop, J Flesche, H van Goor, AD Kistler, M Bakker, RJ Bindels, RA de Boer, CC Möller, I Hamming, G Navis, JF Wetzels, JH Berden, J Reiser, C Faul, and J van der Vlag Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway Am J Pathol 179 2011 1719 1732
37. R Zietse, GJ Wenting, P Kramer, MA Schalekamp, and W Weimar Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome Clin Sci (Lond) 82 1992 641 650
38. MJ Townsend, JG Monroe, and AC Chan B-cell targeted therapies in human autoimmune diseases: an updated perspective Immunol Rev 237 2010 264 283
39. F Perosa, E Favoino, MA Caragnano, and F Dammacco Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor Blood 107 2006 1070 1077
40. AD Salama, and CD Pusey Drug insight: rituximab in renal disease and transplantation Nat Clin Pract Nephrol 2 2006 221 230
41. K Nozu, K Iijima, M Fujisawa, A Nakagawa, N Yoshikawa, and M Matsuo Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome Pediatr Nephrol 20 2005 1660 1663
42. MD Pescovitz, BK Book, and RA Sidner Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment N Engl J Med 354 2006 1961 1963
43. A Fornoni, J Sageshima, C Wei, S Merscher-Gomez, R Aguillon-Prada, AN Jauregui, J Li, A Mattiazzi, G Ciancio, L Chen, G Zilleruelo, C Abitbol, J Chandar, W Seeherunvong, C Ricordi, M Ikehata, MP Rastaldi, J Reiser, and GW Burke 3rd Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis Sci Transl Med 3 2011 85ra46
44. TH Yoo, CE Pedigo, J Guzman, M Correa-Medina, C Wei, R Villarreal, A Mitrofanova, F Leclercq, C Faul, J Li, M Kretzler, RG Nelson, M Lehto, C Forsblom, PH Groop, J Reiser, GW Burke, A Fornoni, and S Merscher Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease J Am Soc Nephrol 26 2015 133 147
45. LV Riella, and MH Sayegh T-cell co-stimulatory blockade in transplantation: two steps forward one step back! Expert Opin Biol Ther 13 2013 1557 1568
46. L Moreland, G Bate, and P Kirkpatrick Abatacept Nat Rev Drug Discov 5 2006 185 186
47. B Chopra, and KK Sureshkumar Co-stimulatory blockade with belatacept in kidney transplantation Expert Opin Biol Ther 14 2014 563 567
48. J Reiser, G von Gersdorff, M Loos, J Oh, K Asanuma, L Giardino, MP Rastaldi, N Calvaresi, H Watanabe, K Schwarz, C Faul, M Kretzler, A Davidson, H Sugimoto, R Kalluri, AH Sharpe, JA Kreidberg, and P Mundel Induction of B7-1 in podocytes is associated with nephrotic syndrome J Clin Invest 113 2004 1390 1397
49. S Bhat, and MS Czuczman Galiximab: a review Expert Opin Biol Ther 10 2010 451 458
50. S Vinjamaram, MS Czuczman, and FJ Hernandez-Ilizaliturri The use of galiximab in non-Hodgkin lymphoma Clin Lymphoma Myeloma 8 2008 277 282
51. CC Yu, A Fornoni, A Weins, S Hakroush, D Maiguel, J Sageshima, L Chen, G Ciancio, MH Faridi, D Behr, KN Campbell, JM Chang, HC Chen, J Oh, C Faul, MA Arnaout, P Fiorina, V Gupta, A Greka, GW Burke 3rd, and P Mundel Abatacept in B7-1-positive proteinuric kidney disease N Engl J Med 369 2013 2416 2423
52. T Hla, MJ Lee, N Ancellin, JH Paik, and MJ Kluk Lysophospholipids - receptor revelations Science 294 2001 1875 1878
53. EJ Goetzl, JJ Liao, and MC Huang Regulation of the roles of sphingosine 1-phosphate and its type 1 G protein-coupled receptor in T cell immunity and autoimmunity Biochim Biophys Acta 1781 2008 503 507
54. P O'Connor, G Comi, X Montalban, J Antel, EW Radue, A de Vera, H Pohlmann, and L Kappos FTY720 D2201 Study Group: Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study Neurology 72 2009 73 79
55. L Kappos, J Antel, G Comi, X Montalban, P O'Connor, CH Polman, T Haas, AA Korn, G Karlsson, and EW Radue FTY720 D2201 Study Group: Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 2006 1124 1140
56. AS Awad, H Ye, L Huang, L Li, FW Foss Jr, TL Macdonald, KR Lynch, and MD Okusa Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney Am J Physiol Renal Physiol 290 2006 F1516 F1524
57. AS Awad, MD Rouse, K Khutsishvili, L Huang, WK Bolton, KR Lynch, and MD Okusa Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes Kidney Int 79 2011 1090 1098
58. T Schwecke, JF Aparicio, I Molnár, A König, LE Khaw, SF Haydock, M Oliynyk, P Caffrey, J Cortés, JB Lester, GA Böhm, J Staunton, and PF Leadlay The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin Proc Natl Acad Sci U S A 92 1995 7839 7843
59. N Hay, and N Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945
60. AB Fogo The targeted podocyte J Clin Invest 121 2011 2142 2145
61. M Dodson, V Darley-Usmar, and J Zhang Cellular metabolic and autophagic pathways: traffic control by redox signaling Free Radic Biol Med 63 2013 207 221
62. MZ Zhang, Y Wang, P Paueksakon, and RC Harris Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy Diabetes 63 2014 2063 2072
63. K Inoki, H Mori, J Wang, T Suzuki, S Hong, S Yoshida, SM Blattner, T Ikenoue, MA Rüegg, MN Hall, DJ Kwiatkowski, MP Rastaldi, TB Huber, M Kretzler, LB Holzman, RC Wiggins, and KL Guan mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice J Clin Invest 121 2011 2181 2196
64. M Gödel, B Hartleben, N Herbach, S Liu, S Zschiedrich, S Lu, A Debreczeni-Mór, MT Lindenmeyer, MP Rastaldi, G Hartleben, T Wiech, A Fornoni, RG Nelson, M Kretzler, R Wanke, H Pavenstädt, D Kerjaschki, CD Cohen, MN Hall, MA Rüegg, K Inoki, G Walz, and TB Huber Role of mTOR in podocyte function and diabetic nephropathy in humans and mice J Clin Invest 121 2011 2197 2209
65. F Diekmann, A Andrés, and F Oppenheimer mTOR inhibitor-associated proteinuria in kidney transplant recipients Transplant Rev (Orlando) 26 2012 27 29
66. R. Gong The renaissance of corticotropin therapy in proteinuric nephropathies Nat Rev Nephrol 8 2011 122 128
67. L.H. Beck Jr, and D.J. Salant Membranous nephropathy: from models to man J Clin Invest 124 2014 2307 2314